Common stock, par value $0.001 per share
- Symbol
- LAB
- Exchange
- NASDAQ
- Classification
- COMMON
- Status
- Current
Current Report · Items 7.01, 9.01 · 8-K
Standard BioTools Inc.
LABNASDAQEQUITYCurrent
Regulation FD Disclosure
Item 7.01 Regulation FD Disclosure. On November 3, 2026, Standard BioTools Inc., a Delaware corporation (“Standard BioTools”), issued a joint press release with ARCHIMED, a leading investment firm focused exclusively on healthcare industries (“ARCHIMED”), announcing the closing of Standard BioTools’ previously announced sale of its Microfluidics business to ARCHIMED.…
Company context
Standard BioTools Inc. (NASDAQ: LAB), is committed to setting the new standard in the life science tools industry through strategic consolidation, best-in-class operations and a world class management team. Standard BioTools’ established portfolio includes essential, standardized next-generation solutions designed to help biomedical researchers develop better therapeutics faster. Learn more at standardbio.com or connect with us on X, Facebook®, LinkedIn, and YouTube™.
Current securities
Historical securities (1)
Registered securities in this filing
Standard BioTools Inc. · 8-K · Filed 2026-11-03
Disclosure sections
Item 7.01Item 7.01 - Regulation FD Disclosure
Item 7.01 Regulation FD Disclosure.
On November 3, 2026, Standard BioTools Inc., a Delaware corporation (“Standard BioTools”), issued a joint press release with ARCHIMED, a leading
investment firm focused exclusively on healthcare industries (“ARCHIMED”), announcing the closing of Standard BioTools’ previously announced sale of its Microfluidics business to ARCHIMED. A copy of the press release is furnished as Exhibit 99.1
hereto and is incorporated herein by reference.
The information set forth in this Item 7.01 and in the attached Exhibit 99.1 shall not be deemed “filed” for purposes of Section 18 of the Securities
Exchange Act of 1934, as amended (the “Exchange Act”), or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.
Filed exhibits (1)
Exhibit 99.1 ARCHIMED Life Science Tools & Services Completes Acquisition of Standard BioTools’ Microfluidics Business, Now Biomark Scientific Business will operate as Biomark Scientific, a leader in accessible, scalable and automated genomic workflows powered by proprietary microfluidics technology November 3, 2026 - Global private equity healthcare specialist ARCHIMED, and Standard BioTools Inc. (NASDAQ: LAB) (“Standard BioTools”), today announced the completion of ARCHIMED’s previously announced acquisition of Standard BioTools’ Microfluidics Business. As part of ARCHIMED, the business enters its next chapter as a standalone business under the name Biomark Scientific. Biomark Scientific, an innovative microfluidics technology tools provider specializing in high-throughput and multi-assay genomics systems, will offer versatile and scalable genomic profiling on its flagship Biomark™ platform. The next-generation Biomark X9 system is the only automated PCR, qPCR and NGS library prep system on the market, performing simultaneous profiling of multiple types of genomic assay readouts in a single run using patented integrated fluidic circuits (IFCs). A highly regarded brand in hig…
Open exhibit ↗